Los Angeles Capital Management LLC Reduces Stock Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Los Angeles Capital Management LLC lowered its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 11.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 301,344 shares of the medical instruments supplier’s stock after selling 39,781 shares during the quarter. Los Angeles Capital Management LLC owned about 0.41% of OraSure Technologies worth $1,284,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of OraSure Technologies in the first quarter valued at about $72,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of OraSure Technologies in the fourth quarter valued at about $113,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of OraSure Technologies in the fourth quarter valued at about $115,000. Tocqueville Asset Management L.P. lifted its position in OraSure Technologies by 20.0% in the first quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock valued at $93,000 after buying an additional 2,512 shares during the last quarter. Finally, Tidal Investments LLC acquired a new position in OraSure Technologies in the first quarter valued at about $116,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on OSUR. Evercore ISI upped their target price on shares of OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research report on Wednesday, August 7th. StockNews.com cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, August 17th. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, OraSure Technologies currently has a consensus rating of “Hold” and a consensus target price of $6.67.

OraSure Technologies Stock Performance

Shares of OSUR opened at $4.25 on Thursday. The stock has a market capitalization of $314.33 million, a PE ratio of 14.17 and a beta of 0.05. OraSure Technologies, Inc. has a 1 year low of $3.91 and a 1 year high of $8.45. The company’s 50-day simple moving average is $4.30 and its 200-day simple moving average is $5.08.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $53.35 million. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. On average, sell-side analysts predict that OraSure Technologies, Inc. will post -0.11 earnings per share for the current year.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.